Covid-19 and Cancer

Öz

SARS-CoV-2, the new member of the coronavirus family, is a virus that emerged in Wuhan, China in December 2019 and caused a pandemic all over the world. This disease, called Covid-19, increases the risk of death in individuals over 65 years of age and with chronic diseases. Cytokine Storm is one of the most serious mechanisms that trigger death in the pathogenesis of Covid-19. Although studies are ongoing for a vaccine against this disease or a drug that will affect its pathogenesis, an effective treatment method has not been found. The rapid spread of the virus and the increase in the number of cases have caused a problems in the health sector, and guidelines have been published to reduce the risk of infection of individuals who have not been diagnosed with Covid-19 but have serious illnesses such as cancer. In this review, we will discuss the origin and pathology of Covid-19, why its mortality is higher in certain situations, as well as the effect of this disease on the life of cancer patients, complications in cancer patients diagnosed with Covid-19, the effect of inhibitors used in cancer treatment on Covid-19 and lastly guidelines and studies will be discussed for cancer patients in global pandemic.

Anahtar Kelimeler

• SARS-CoV-2
• Covid-19
• Cancer
• Cytokine
• ACE2

Covid-19 ve Kanser

Öz

2019 Aralık Ayında Çin’in Wuhan şehrinde ortaya çıkan ve koronavirüs ailesinin yeni üyesi olan SARS-CoV-2 kısa sürede tüm Dünya’ya yayılmış ve pandemi ilan edilmesine neden olmuş bir virüstür. Covid-19 olarak adlandırılan bu hastalık kronik rahatsızlığı bulunan ve yaşı 65 üzeri olan bireylerde ölüm riskini arttırmaktadır. Covid-19’un patogenezinde ölümü tetikleyen en ciddi mekanizmaların başında oluşturduğu Sitokin Fırtınası gelmektedir. Günümüzde hastalığa karşı aşı veya bu mekanizmaları düzenleyecek bir ilaç araştırmaları devam etse de ne yazık ki henüz net bir tedavi yöntemi bulunmamaktadır. Hızlı yayılması ve vaka sayılarındaki artış sağlık sektöründe büyük bir yoğunluğa neden olduğu için Covid-19 tanısı konmayan fakat kanser gibi ciddi rahatsızlıkları olan bireylerin enfekte olma riskini azaltmaya yönelik kılavuzlar yayınlanmıştır. Bu derlemede Covid-19'un kökenini, patolojisini, neden mortalitesinin belirli durumlarda yüksek olduğunun yanı sıra bu hastalığın kanserli hastaların hayatına olan etkisi, Covid-19 tanısı konulan kanser hastalarının tedavisindeki komplikasyonlar ve kanser tedavisinde kullanılan inhibitörlerin Covid-19 üzerine etkisini kapsayan tedavi biçimlerini içeren kılavuz ve çalışmalar tartışılacaktır.

Anahtar Kelimeler

• SARS-CoV-2
• Covid-19
• Kanser
• Sitokin
• ACE2

Kaynakça

1. Lu R, Zhao X, Li J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395:565–574
2. Paraskevis D, Kostaki EG, Magiorkinis G et al. Tsiodras S Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol 2020; 79:104212
3. Chen L, Liu W, Zhang Q et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microb Infect 2020; 9:313–319
4. Yuki, K., Fujiogi, M., & Koutsogiannaki, S. COVID-19 pathophysiology: A review. Clin Immunol 2020; 108427.
5. Madabhavi, I., Sarkar, M., & Kadakol, N. COVID-19: a review. Monaldi Arch Chest Dis 2020; 90(2).
6. WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 40. Available at: https://covid19.who.int
7. Mousavizadeh, L., & Ghasemi, S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2020; https://doi.org/10.1016/j.jmii.2020.03.022.
8. Hassan, S. S., Choudhury, P. P., & Roy, B. Molecular phylogeny and missense mutations of envelope proteins across coronaviruses. Genomics 2020; 112(6): 4993–5004.

9. Ge, H., Wang, X., Yuan, X et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020; 14:1–9.
10. Li, H., Liu, S. M., Yu, X. H et al. Coronavirus disease 2019 (COVID-19): current status and future perspective. Int J Antimicrob Agents. 2020; 55(5):105951.
11. Nikolich-Zugich, J., Knox, K. S., Rios, C. T et al. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience; 2020; 42(2): 505–514.
12. Jin, Y., Yang, H., Ji, W et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12(4), 372.
13. Fan, C., Li, K., Ding, Y et al. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. MedRxiv 2020; 53:66-70. https://doi.org/10.1101/2020.02.12.20022418
14. Ye, Q., Wang, B., & Mao, J. The pathogenesis and treatment of theCytokine Storm'in COVID-19. J Infect 2020; 80(6), 607-613.
15. Mahmudpour, M., Roozbeh, J., Keshavarz M et al. COVID-19 cytokine storm: The anger of inflammation. Cytokine 2020; 155151.
16. Ragab, D., Salah Eldin, H., Taeimah et al. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020; 11, 1446.
17. Touma, M. COVID-19: molecular diagnostics overview. J Mol Med (Berl) 2020; 1-8.
18. Nile, S. H., Nile, A., Qiu, J., et al. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev 2020; 53: 66–70.
19. Hu, B., Huang, S., & Yin, L. The cytokine storm and COVID‐19. J Med Virol 2020; 1–7.
20. Hirano, T., & Murakami, M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020; 52(5)731-733.
21. Nasonov, E., & Samsonov, M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother 2020; 131:110698.
22. Scherger, S., Henao-Martínez, A., Franco-Paredes, C., & Shapiro, L. Rethinking interleukin-6 blockade for treatment of COVID-19. Med Hypotheses 2020; 144, 110053.
23. Takayama, K. In vitro and Animal Models for SARS-CoV-2 research. Trends Pharmacol Sci 2020; 41(8):513-517.
24. Suzuki, T., Ito, Y., Sakai, Y et al. Generation of human bronchial organoids for SARS-CoV-2 research. bioRxiv 2020; 115600. https://doi.org/10.1101/2020.05.25.115600.
25. Han, Y., Yang, L., Duan, X et al. Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids. bioRxiv 2020; 079095. https://doi.org/10.1101/2020.05.05.079095.
26. Monteil, V., Kwon, H., Prado, P et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181(4):905-913.e7.
27. Varga, Z., Flammer, A. J., Steiger, P et al. H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395(10234), 1417-1418.
28. Zhao, B., Ni, C., Gao, R et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell 2020; 1-5.
29. Addeo, A., & Friedlaender, A. Cancer and COVID-19: unmasking their ties. Cancer Treat Rev. 2020; 88:102041.
30. Liu, C., Zhao, Y., & Okwan-Duodu, D. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med 2020; 17(3), 519-527.
31. Gosain, R., Abdou, Y., Singh, A et al. COVID-19 and cancer: a comprehensive review. Curr Oncol Rep 2020; 22(5):53.
32. Catanese, S., Pentheroudakis, G., Douillard, J. Y., & Lordick, F. ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open 2020 5(Suppl 3), e000804.
33. Sharpless NE. COVID-19 and cancer. Science. 2020; 368(6497):1290. doi: 10.1126/science.abd3377.
34. Lee, L. Y., Cazier, J. B., Starkey, T., Turnbull, C. D et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395(10241) 1919-1926.
35. Extance, A. Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?. BMJ 2020; 368.
36. Chen, H., Wu, X., Wang, W., & Wang, Q. When cancer encounters COVID-19 in China: what have we suffered, experienced and learned. Jpn J Clin Oncol 2020; 50(6), 712-717.
37. Guan, W. J., Liang, W. H., Zhao, Y et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020; 55(5).
38. Tian, S., Hu, W., Niu, L et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020; 15(5): 700–704.
39. Sidaway, P. COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol 2020; 17(6):336.
40. Kotecha, R. S. Challenges posed by COVID-19 to children with cancer. The Lancet Oncology 2020; 21(5), e235.
41. Yu, J., Ouyang, W., Chua, M. L., & Xie, C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108–1110. doi:10.1001/jamaoncol.2020.0980.
42. Dai, M., Liu, D., Liu, M et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020; 10(6), 783-791.
43. Al‐Shamsi, H. O., Alhazzani, W., Alhuraiji, A et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group. Oncologist 2020; 25(6), e936.
44. Routy, B., Derosa, L., Zitvogel, L., & Kroemer, G. COVID-19: a challenge for oncology services. Oncoimmunology 2020; 9(1): 1760686.
45. Tartarone, A., & Lerose, R. COVID-19 and cancer care: what do international guidelines say?. Med Oncol 2020 37(9), 1-5.
46. CDC. Guidance for COVID-19. Available at: https://cdc.gov/coronaviru s/2019-ncov/hcp/clinical-criteria.html.
47. National Institute for Health and Care Excellence. COVID‐19 rapid guideline: delivery of systemic anticancer treatments, NICE guideline, Available at: http://nice.org.uk/guidance/ng161.
48. Cortiula, F., Pettke, A., Bartoletti, M et al. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann Oncol 2020; 31(5), 553-555.
49. Al-Quteimat, O. M., & Amer, A. M. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol 2020; 00:000–000. doi: 10.1097/COC.0000000000000712.
50. Kuderer, N. M., & Lyman, G. H. COVID-19, Cancer, and Consequences: Where Are We Now?. Cancer Invest 2020; 1-5.
51. Cai, C., Ahmed, O. A., Shen, H., & Zeng, S. Which cancer type has the highest risk of COVID-19 infection?. J Infect 2020; 81(4): 647–679.
52. Che, Q., Liu, B. Y., Wang, F. Y et al. Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK–NF-κB signaling pathway. Biochem Biophys Res Commun 2014; 446(1), 167-172.
53. Zhang, C., Wu, Z., Li, J. W et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020; 105954.
54. Klein, E. A., Li, J., Milinovich, A et al L. Androgen Deprivation Therapy in Men With Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. J Urol 2020; 10-1097.
55. Akula, S. M., Abrams, S. L., Steelman, L. S et al. Cancer therapy and treatments during COVID-19 era. Adv Biol Regul 2020; 100739.